Biopharma capacity crunch shifts focus to ready-now manufacturing hubs like Middlesex County, NJ

Demand for biopharma manufacturing, especially cell and gene therapies, is growing faster than the ability to build new GMP-ready facilities, which can take years to complete.

To keep pace, companies are seeking sites that already have the necessary infrastructure, such as certified clean rooms, robust utilities and cold-chain logistics.

Middlesex County in New Jersey is highlighted as a ready-now location, with existing GMP-capable plants, an established workforce and easy access to major ports and airports.

A biopharma executive is quoted saying the industry needs infrastructure that is ready now, allowing rapid move from planning to production.